Annual rank45
Belgium · Healthcare
Ucb
Focuses on creating solutions intended to improve life for people living with neurological and autoimmune conditions.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Medicines, research platforms and supply for severe diseases
UCB is a Belgian biopharmaceutical group focused on severe neurological and immune-mediated diseases. Its portfolio spans epilepsy, rare neurological conditions, myasthenia gravis, inflammatory disease and osteoporosis. Behind those medicines is a research system working across antibodies, peptides, small molecules, drug-device combinations and gene therapy, supported by clinical-study infrastructure and manufacturing sites in Europe, Japan and the United States.
Neurology medicines
Different formats for epilepsy, gMG and an ultra-rare mitochondrial disease
UCB's neurology portfolio includes Briviact for focal seizures and Fintepla for seizures associated with Dravet and Lennox-Gastaut syndromes. Rystiggo and Zilbrysq address defined forms of generalised myasthenia gravis through different active substances. KYGEVVI is a powder for oral solution approved in the US and authorised under exceptional circumstances in the EU for genetically confirmed TK2 deficiency with symptom onset on or before age 12; UCB describes it as the first and only approved treatment for that population. Availability and approved uses vary by country.
- Read the KYGEVVI indication and approval boundary TK2d population, US and EU status and safety-information context
- Medicine directory The complete UCB list with diseases and country-specific information
- Briviact Brivaracetam and its approved epilepsy settings
- Fintepla Fenfluramine for Dravet and Lennox-Gastaut syndromes
- Rystiggo Rozanolixizumab in generalised myasthenia gravis
- Zilbrysq Zilucoplan in generalised myasthenia gravis
Immunology and bone health
One portfolio crosses skin, joints, bowel and bone
BIMZELX is reported across five approved indications: plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. UCB says more than 135,000 patients had been treated by H1 2026. CIMZIA is used across several inflammatory conditions, while EVENITY sits in osteoporosis. The portfolio is organised around connected inflammatory pathways rather than a single diagnosis; availability and approved uses vary by country.
- Open the H1 BIMZELX scale update Five indications, patient count, sales mix and BE BOLD evidence
- Bimzelx Bimekizumab and its approved inflammatory-disease settings
- Cimzia An example of certolizumab pegol across inflammatory disease
- Evenity Romosozumab in osteoporosis
- Immunology at UCB The disease areas and portfolio logic behind the medicines
Discovery and development
From macrocyclic peptides to T-cell engagers and cell therapy
UCB's discovery toolkit includes small molecules, antibodies, AAV vectors and the ExtremeDiversity platform for synthetic macrocyclic peptides. The pipeline now also includes cizutamig, an investigational BCMA by CD3 T-cell engager, and rezanecel, an investigational allogeneic GABA interneuron cell therapy administered through a one-time minimally invasive procedure. Cizutamig Phase 2 studies are planned by end-2026 and rezanecel Phase 3 for H1 2027; neither asset is approved. The clinical-study library shows how programmes are tested and disclosed.
- Open the completed Candid acquisition Cizutamig and the investigational immune-reset platform
- Open the completed Neurona acquisition Rezanecel, regenerative medicine and the investigational boundary
- Clinical pipeline Named assets, modalities, indications and development stages
- Drug-discovery platforms Small molecules, antibodies, peptides and AAV vectors
- Clinical studies at UCB Study transparency, registries and the development process
- ▶ VideoWatch: how medicines are tested UCB's English overview of the clinical-study journey
Research, supply and lived experience
A network that connects laboratories, plants and patients
Braine-l'Alleud combines research and manufacturing, Bulle brings biotechnology and chemical production together, and UCB has added a gene-therapy pilot plant in Belgium while planning biologics capacity in Georgia. The Faces of MG project places this infrastructure beside first-person accounts of living with myasthenia gravis.
- Global R&D locations Research and manufacturing roles from Belgium to Japan and the US
- Braine biotechnology plant The site's shift from small molecules towards biologics
- Inside the gene-therapy facility A 1,200-square-metre clinical manufacturing pilot plant
- Georgia manufacturing project Planned US biologics capacity, automation and local skills
- Faces of MG Photography and first-person stories about myasthenia gravis
Official profile sources: About UCB | UCB · UCB Further Facts & Figures · UCB Integrated Annual Report 2025
Current 2026 update
What is changing at UCB in 2026?
UCB is scaling BIMZELX across five immune diseases while commercialising an ultra-rare treatment and adding an investigational T-cell engager and cell therapy.
The change in one sentence
Commercial scale and two acquisitions are reshaping the portfolio at the same time.
BIMZELX and KYGEVVI expand approved medicines; Candid and Neurona add investigational immune-reset and regenerative platforms with future trial milestones.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Approved portfolio
BIMZELX scales across diseases; KYGEVVI records early sales
H1 BIMZELX sales reached EUR 1.528 billion, up 91%, with more than 135,000 patients treated. Psoriasis generated 45% of sales, hidradenitis suppurativa 33%, and the other three approved indications 22%. BE BOLD achieved ACR50 superiority over risankizumab in psoriatic arthritis, and peak-sales guidance rose to at least EUR 7 billion. KYGEVVI H1 sales were EUR 5 million. Separately, the European Commission granted marketing authorisation under exceptional circumstances in March for genetically confirmed TK2 deficiency with symptom onset on or before age 12. UCB describes it as the first and only approved treatment for that population.
- Current signalBIMZELX EUR 1.528bn and 135,000+ patients · five indications · KYGEVVI first EUR 5m
- Why it mattersUCB now has both a broad immune-disease franchise and an early ultra-rare launch; later disclosures must show access, patient adoption and durability.
- H1 commercial and pipeline update UCB · 2026-07-30
- H1 report and acquisition accounting UCB · 2026-07-30
- KYGEVVI indication and approval context UCB · 2026-06-17
02 · Immune reset
Candid adds an investigational T-cell engager platform
UCB completed the Candid acquisition on 16 June. Cizutamig is an investigational bispecific antibody targeting BCMA on plasma cells and CD3 on T cells, enabling T-cell-mediated cytotoxicity against BCMA-expressing plasma cells and B cells. Phase 2 studies in myasthenia gravis and systemic autoimmune rheumatic disease-associated interstitial lung disease are planned by end-2026. UCB paid USD 2 billion upfront and may pay up to USD 200 million in milestones. The acquisition and trial plans do not establish safety, efficacy, approval or a launch timetable.
- Current signalUSD 2bn upfront · up to USD 200m milestones · two Phase 2 starts planned by year-end
- Why it mattersCandid moves UCB into immune-reset technology beyond its approved medicines, but the scientific and commercial proof still lies ahead.
- Candid completion and cizutamig UCB · 2026-06-17
- H1 report and acquisition accounting UCB · 2026-07-30
- Current cizutamig and rezanecel pipeline UCB · 2026-08-28
03 · Regenerative neurology
Rezanecel adds cell therapy to the epilepsy portfolio
UCB completed Neurona on 1 June, paying USD 650 million upfront with up to USD 500 million in future milestones. Rezanecel is an investigational allogeneic GABA interneuron cell therapy administered in a one-time minimally invasive procedure and designed to integrate into dysregulated neural circuits; Phase 3 is planned for H1 2027. It is not approved. Separately, BRIVIACT sales fell 13% after US loss of exclusivity, with European loss expected in August. Neurona, Candid, the dividend and treasury-share purchases were the disclosed main reasons net financial debt reached EUR 2.821 billion from EUR 7 million net cash; leverage was 0.8x.
- Current signalUSD 650m upfront · Phase 3 planned H1 2027 · BRIVIACT −13% · net debt EUR 2.821bn
- Why it mattersRegenerative medicine could extend UCB's epilepsy portfolio beyond established drugs, while trial execution and acquisition integration remain unproven.
- Neurona completion and rezanecel UCB · 2026-06-02
- H1 report and acquisition accounting UCB · 2026-07-30
- Current cizutamig and rezanecel pipeline UCB · 2026-08-28
04 · What to watch
Three questions for the next disclosures
The next disclosures should keep approved products separate from investigational platforms and acquisition cost separate from clinical proof.
- Approved-product adoptionDoes BIMZELX maintain multi-indication growth, and what patient or access evidence emerges for the early KYGEVVI launch?
- Cizutamig trialsDo both Phase 2 studies begin by year-end, and when does UCB disclose meaningful safety and efficacy evidence?
- Rezanecel and integrationCan UCB start Phase 3 in H1 2027 and integrate both acquisitions while keeping development milestones and leverage controlled?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 45 | +40% | +273% | +236% |